Drug
Biktarvy
Biktarvy: highest development phase Post-Market, developed by Gilead Sciences. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Biktarvy 50Mg-200Mg-25Mg Tablet NCT04650269 | Post-Market | Harm Reduction |
Latest
No recent events.
Follow Biktarvy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.